Wire · regulatory
FDA's Generative AI Discussion Paper Signals a Break from the Past in Terminology, But ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
The FDA's discussion paper on generative AI-enabled medical devices signals a terminological shift away from previous AI regulatory language but retains familiar risk-based regulatory principles. The paper invites public feedback by October 19, 2026, marking a potential shift in how generative AI medical software may be regulated.
This Wire brief sits within Fusion42's coverage of Medtech, and 14 sources have reported it between 18 Aug 2026 and 15 Sep 2026.
◆ ◆ The Wire takeaway
You must reassess your regulatory strategy as the FDA drops old AI terms and hints at a new approach to generative AI in medical devices. Start preparing feedback now to influence rules that could reshape compliance and product design.
◆ Coverage
14 sources · first reported 18 Aug 2026 · latest 15 Sep 2026
◆ Related on Wire
◆ Topics